ALLK News and Press, Allakos Inc. From 09/27/23

2023-09-27 14:47:10 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For further details see: Allokos ...

2023-09-27 12:10:16 ET Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. The stock got a boost when an analyst initiated coverage. Despite the rise, Allakos' stock is still down more than 70% so far this year. Al...

2023-09-27 09:59:57 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

2023-09-27 08:30:53 ET MillerKnoll  ( MLKN ) +17% rides 18% higher, sees improving organic orders during FQ1. Gaucho Group Holdings  ( VINO ) +15% . Ginkgo Bioworks Holdings  ( DNA ) +16% Announces Multi-Target RNA Discovery Collaboration w...

2023-09-18 02:07:15 ET Summary Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-...

2023-09-11 17:20:07 ET Gainers: Matrix Service  ( MTRX ) +10% . Adeia  ( ADEA ) +7% . Allakos  ( ALLK ) +5% . Nurix Therapeutics ( NRIX ) +5% . ADMA Biologics ( ADMA ) +4% . Losers: ACELYRIN ( SLRN ) ...

SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...

2023-08-09 17:54:54 ET Allakos press release ( NASDAQ: ALLK ): Q2 GAAP EPS of -$0.41 beats by $0.08 . Allakos ended the second quarter of 2023 with $221.1 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and invest...

SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results fo...

SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...